<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">38331138</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-7162</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>The American journal of medicine</Title><ISOAbbreviation>Am J Med</ISOAbbreviation></Journal><ArticleTitle>Factors Associated with Cognitive Impairment in Patients with Persisting Sequelae of COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0002-9343(24)00058-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjmed.2024.01.021</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Quantify cognitive deficits in patients with postacute sequelae of COVID-19 (PASC) and identify key variables related to cognitive impairment in PASC.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Patients with polymerase chain reaction-confirmed COVID-19 underwent a comprehensive neuropsychological evaluation. The comparison group included patients without neurological disorders determined by the neuropsychologist to be cognitively intact. Cognitive impairment was defined as impairment (Composite T &#x2264;35) in 1 of 6 cognitive domains. The PASC group was split into impaired or intact based on the above criteria. Multivariable logistic regression models assessed predictors including demographics, COVID-19 severity, clinical characteristics, and mood.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 210 patients with PASC, predominantly female (73.3%, P &lt; .001), without other demographic differences when compared with 369 normal controls. Patients with PASC were more likely to have cognitive impairment (odds ratio 3.61; 95% confidence interval, 2.36-5.54; P &lt; .001) compared with controls, with significantly lower scores in domains of memory, language, processing speed, visuospatial function, executive function (P &lt; .001), and higher depressive (P = .004) and anxiety symptoms (P = .003). Patients with PASC who demonstrated cognitive impairment (n = 93) had higher body mass index compared with those with PASC without cognitive impairment (n = 117), without differences in other predictors.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with PASC are almost 4 times more likely to evidence cognitive dysfunction compared with normal controls. Forty-four percent of patients with PASC demonstrated cognitive deficits about 7 months from infection. Estimated premorbid intelligence significantly correlated with impairment. Higher body mass index was the only metric shown to differentiate those with PASC and cognitive impairment from those with PASC who were cognitively intact.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonner-Jackson</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurological Institute, Section of Neuropsychology; Lou Ruvo Center for Brain Health, Cleveland Clinic, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vangal</LastName><ForeName>Rohun</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Toledo College of Medicine and Life Sciences, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yadi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research &amp; Evaluation, Neurological Institute, Cleveland Clinic, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research &amp; Evaluation, Neurological Institute, Cleveland Clinic, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakrabarti</LastName><ForeName>Shinjon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>Kamini</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurological Institute, Section of Neuropsychology; Lou Ruvo Center for Brain Health, Cleveland Clinic, Ohio. Electronic address: kkrishnan.np@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med</MedlineTA><NlmUniqueID>0267200</NlmUniqueID><ISSNLinking>0002-9343</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cognitive impairment</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Long-COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">Neuropsychological abnormalities</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>9</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>9</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38331138</ArticleId><ArticleId IdType="doi">10.1016/j.amjmed.2024.01.021</ArticleId><ArticleId IdType="pii">S0002-9343(24)00058-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>